Comparative Pharmacology
Head-to-head clinical analysis: OSMITROL 15 IN WATER IN PLASTIC CONTAINER versus SORBITOL MANNITOL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSMITROL 15 IN WATER IN PLASTIC CONTAINER versus SORBITOL MANNITOL IN PLASTIC CONTAINER.
OSMITROL 15% IN WATER IN PLASTIC CONTAINER vs SORBITOL-MANNITOL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Osmotically active agent that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing cerebral edema and intraocular pressure.
Sorbitol and mannitol are osmotic diuretics. They increase osmotic pressure in the glomerular filtrate, reducing water reabsorption and promoting diuresis. Mannitol also decreases intracranial and intraocular pressure by creating an osmotic gradient that draws water from tissues into the vasculature.
1.5-2 g/kg intravenous infusion over 30-60 minutes every 6-8 hours as needed for reduction of intracranial pressure or cerebral edema.
Intravenous infusion of 50 mL of a 25% sorbitol-25% mannitol solution administered over 10–20 minutes; may repeat once after 6–8 hours if needed.
None Documented
None Documented
Terminal half-life: 0.25–1.5 hours (15–90 minutes) in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Sorbitol: approximately 0.5-1 hour; mannitol: approximately 0.5-1.5 hours. In anuria, mannitol half-life may extend to 36 hours.
Renal: >90% unchanged by glomerular filtration; minimal tubular reabsorption or secretion. <10% metabolized in liver (negligible).
Renal: >95% as unchanged sorbitol and mannitol; negligible biliary/fecal elimination.
Category C
Category A/B
Osmotic Diuretic
Osmotic Diuretic